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Abstract
Background: Pancreatic juice cytology (PJC) is a tool for diagnosing malignant intraductal papillary mucinous
neoplasm (IPMN); however, the accuracy is insufficient using the conventional method. Liquid-based cytology (LBC)
improves the cell recovery rate, and almost all cells can be evaluated. We evaluated the efficacy of PJC with LBC for
malignant IPMN.
Methods: We retrospectively analyzed 90 patients with suspected malignant IPMN who underwent PJC before
pancreatectomy. PJC with smear and LBC methods was conducted in 52 patients (between June 2003 to December
2011) and 38 patients (between January 2012 to December 2018). Based on the imaging studies, all of the patients
were classified according to the international consensus guidelines for IPMN revised in 2017.
Results: Of the 90 patients, 43 (48%) had malignant IPMN (high-grade dysplasia or invasive carcinoma), and the
remaining patients had non-malignant IPMN (intermediate- or low-grade dysplasia). LBC increased the accuracy
of PJC for the diagnosis of malignant IPMN (smear method: 56% [29/52] vs. LBC method: 76% [29/38]; P = 0.044). In a
multivariate analysis, LBC was a significant factor influencing the accurate diagnosis of PJC (odds ratio: 3.52; P = 0.021).
Furthermore, LBC increased the accuracy of PJC for malignant IPMN in patients with worrisome features (smear
method: 66% [19/29] vs. LBC method: 93% [14/15]; P = 0.043).
Conclusions: LBC increases the accuracy of PJC for diagnosing malignant IPMN compared with the conventional
smear method.
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Background
The increased detection of pancreatic cysts due to im-
provements in imaging studies has led to a surge in
interest in intraductal papillary mucinous neoplasm
(IPMN). Most IPMNs are benign, but some can progress
to malignant IPMNs. However, it remains difficult to
distinguish malignant IPMN from benign IPMN.
According to the international consensus guidelines
for IPMN revised in 2017 [1], high-risk stigmata (HRS)
were considered a recommended indicator for resection,
and worrisome features (WF) were considered a recom-
mended indicator for further examinations. However,
the rate of malignant IPMN in patients with HRS and
WF were reported to be 49–57% and 16–27%, respect-
ively [2, 3]. Although the presence of mural nodules
(MN) on endoscopic ultrasonography (EUS) has been
shown to be a good predictor of malignant branch duct
IPMN (BD-IPMN) [4–10], about 10% of malignant BD-
IPMNs have been reported in patients without MN
[8, 11, 12]. As mentioned above, the diagnostic ability
of the imaging studies for malignant IPMN is limited.
Pancreatic juice cytology (PJC) under endoscopic retro-
grade cholangiopancreatography (ERCP) is an examin-
ation for IPMNs, and suspicion of malignancy or positive
malignancy by PJC is an absolute indication for resection.
However, the sensitivity of PJC for malignant IPMN was
found to be only 35% in a meta-analysis [13], and the ac-
curacy was also unsatisfactory (33–64%) [2, 14, 15]. Fur-
thermore, the incidence of post-ERCP pancreatitis (PEP)
was also reported to be about 8–25% [2, 14–16]. These
are challenges that must be considered when performing
PJC for the diagnosis of malignant IPMN.
Liquid-based cytology (LBC), developed in 1991 [17],
was originally used in cervical cytology and has since
been widely applied to various organs. LBC has the fol-
lowing benefits: (1) it allows for the efficient transfer of
cells from the collecting device, and almost all cells can
be analyzed; (2) by using separation reagents, it is pos-
sible to selectively reduce red blood cells, inflammatory
cells and mucus—in this way, the cells collected are
mainly those required for the diagnosis, and unsatisfac-
tory smears can be reduced; (3) the cellular materials are
distributed evenly in one spot, leading to a reduction in
screening time; and (4) using residual cellular materials,
immunostaining or genetic tests can be conducted [18].
The effectiveness of LBC has been reported for some
diseases [19–21]; however, no studies have described the
application of LBC in IPMN patients.
Considering the benefits of LBC, it may be useful for
the diagnosis of malignant IPMN with PJC. In the
present study, we retrospectively investigated the efficacy
of PJC using LBC for a malignant IPMN diagnosis.
Methods
Patients
A total of 104 patients with IPMNs who underwent PJC
before pancreatectomy between June 2003 and December
2018 at Okayama University Hospital were retrospectively
Fig. 1 A flowchart for all patients of this study. IPMN, intraductal papillary mucinous neoplasm; PJC, pancreatic juice cytology; CT, computed
tomography; HRS, high-risk stigmata; WF, worrisome features; LBC, liquid-based cytology
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analyzed. PJC was basically performed for the patients
with suspected malignant IPMN due to HRS or WF. PJC
with the smear method was conducted between June 2003
and December 2011, while PJC with LBC was conducted
between January 2012 and December 2018.
Figure 1 shows the study flow chart. Of the 104 patients
with PJC, 5 lacked assessable specimens (smear method: 4,
LBC method: 1). Another five patients who could not
undergo contrast computed tomography (CT) because of
a contrast agent allergy and four who did not satisfy the
HRS or WF criteria were excluded from this study. Ultim-
ately, 90 patients (52 patients with the smear method, 38
patients with LBC) were analyzed. Before endoscopic
retrograde cholangiopancreatography (ERCP), informed
consent was obtained from all patients.
The study was approved by the Okayama University
School of Medicine Clinical Ethics Committee on
Human Experiments in accordance with the Declaration
of Helsinki (Approved number:1904–028).
Methods
The imaging diagnosis
For the imaging studies, all patients underwent EUS and
either or both magnetic resonance cholangiopancreato-
graphy (MRCP) or enhanced CT. The cystic size and
diameter of the main pancreatic duct were evaluated by
MRCP or enhanced CT, while the presence and height
of mural nodules were evaluated by EUS or enhanced
CT. The height of mural nodules was defined as the ver-
tical distance from the septum to the top of the mural
nodule [22]. Based on the imaging studies, all of the pa-
tients were classified as HRS or WF according to the
international consensus guidelines for IPMN revised in
2017 [1].
ERCP procedures and collecting pancreatic juice
ERCP was performed for the patients in a prone or
semi-prone position under conscious sedation using
intravenous diazepam and pethidine hydrochloride with
CO2 insufflation. Pancreatography was carried out using
a duodenoscope (JF260v; Olympus, Tokyo, Japan), and
pancreatic duct cannulation was performed using a long,
tapered catheter (PR-220Q; Olympus) with a 0.025-in.
guidewire (VisiGlide or VisiGlide2; Olympus) or a 0.035-
in. guidwire (RevoWave; Piolax, Kanagawa, Japan). After
cannulation, the cannula was changed to a sampling
catheter with a side hole (PR-130Q; Olympus) or a 6-Fr
uneven double-lumen catheter (UDC; Piolax) with saline
washing. Sampling of the pancreatic juice was carried
out with negative pressure using a 10mL syringe for
about 5 min. A serial pancreatic-juice aspiration cyto-
logic examination (SPACE) was performed using a 5-
French endoscopic naso-pancreatic drainage (ENPD)
tube (Nasal. Pancreatic Drainage Set; Cook Medical,
Japan). In patients with ENPD placement, PJC via an
ENPD tube was able to be repeatedly performed, and
PJC was usually performed 4–5 times over 3–4 days.
The diagnosis of PEP and the severity of PEP were
judged according to the Cotton criteria [23]. PEP was
defined as “clinical pancreatitis with an elevated serum
amylase level >3 times the upper limit of normal after
more than 24 h.” The severity of PEP was as follows:
mild, requiring admission or prolongation of planned ad-
mission to 2–3 days; moderate, requiring hospitalization
of 4–10 days; and severe, requiring hospitalization for
more than 10 days or hemorrhagic pancreatitis, phlegmon,
pseudocyst, or intervention (percutaneous drainage or
surgery).
Preparation of the LBC sample
Figure 2 shows the preparation of the LBC sample with
a schematic illustration. To process LBC samples, a BD
SurePath (Nippon Becton Dickinson Company, Tokyo,
Japan) was used. Pancreatic juice was centrifuged, and
the supernatant fluid was discarded. The material was
suspended in fixative (CytoRich RED; Nippon Becton
Dickinson Company, Tokyo, Japan), and a cell suspen-
sion was prepared. The suspension was centrifuged, and
the supernatant was discarded. The material was then
resuspended in distilled water, and the cell suspension
was poured into a precoat slide equipped with a settling
Fig. 2 Preparation of the LBC sample with a schematic illustration.
First, pancreatic juice was centrifuged, and the supernatant was
discarded. The material was then suspended in fixative (CytoRich™
RED). Next, the suspension was centrifuged, and the supernatant
was discarded. The material was suspended in distilled water. Third,
the cell suspension was poured onto a precoated slide equipped
with a settling chamber. The cells became attached to the slide
glass by the charge and gravity. LBC, liquid-based cytology
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chamber. The cell surface was negatively charged while
the precoated slide was positively charged, and the cells
became attached to the slide glass using the charge and
gravity. Figure 3 shows macro images of the slide glasses
with a schematic illustration. Figure 4 shows the typical
findings of the smear and LBC methods.
Pathological diagnosis
All PJC specimens and the resected specimens were evalu-
ated by two pathologists. The definition of malignancy
with PJC was class IV-V according to the Papanicolaou
classification system [24]. For the resected specimens,
low- to intermediate-grade dysplasia (L-IGD) was deter-
mined to be benign, and high-grade dysplasia (HGD) and
invasive carcinoma (IC) were determined to be malignant
according to the 2010 WHO classification [25].
Evaluating the endpoints
The primary endpoints were the comparison of the diag-
nostic ability of PJC for malignant IPMNs using LBC
and conventional smear methods. The secondary end-
points were the evaluation of the factors contributing to
the accuracy of PJC for the IPMN diagnosis and post-
ERCP adverse events.
Statistical analyses
All statistical analyses were evaluated using the JMP Pro
software program, version 14 (SAS Institute, Cary, NC,
Fig. 3 Macro images of the slide glasses with a schematic illustration: (a) Macro image of smear method. (b) Macro image of LBC. With LBC, the
cellular materials were distributed in two spots. LBC, liquid-based cytology
Fig. 4 PJC findings of malignant IPMN: a A low-power-field image of the smear method. Many inflammatory cells and a large amount of mucus
were found in the background, and the tumor cell cluster was heavily stained. b A high-power-field image of the smear method. It was difficult
to evaluate the cells at the margin of the tumor cell cluster because of overlapping. c A low-power-field image of LBC. There were few
overlapping cells. The background of inflammatory cells and mucus was removed, so the tumor cells scattered solitarily could be evaluated. d A
high-power-field image of LBC. The cells at the margin of the tumor cell cluster could be evaluated. PJC, pancreatic juice cytology; IPMN,
intraductal papillary mucinous neoplasm; LBC, liquid-based cytology
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USA). Pearson’s χ 2 test was used for the categorical var-
iables, whereas the Mann-Whitney U test was used for
continuous data. A multivariate analysis was performed
using logistic regression in order to extract significant
factors contributing to the accuracy of a malignant
IPMN diagnosis. Significant variables in the univariate
analysis (P < 0.2) were selected for inclusion in the multi-
variate model. The significance level was set at P < 0.05.
Results
Patient characteristics
The median age was 70 years old (interquartile range
[IQR]: 65–74 years old). The types of IPMN were as fol-
lows: BD-IPMN, 33 (37%) patients; mixed IPMN, 43
(48%) patients; and main duct (MD)-IPMN, 14 (16%) pa-
tients. Twelve (13%) patients underwent a SPACE. A
SPACE was performed more frequently in the LBC
group than in the smear method group (Table 1) (smear
method: 1/52, 2% vs. LBC: 11/38, 29%; P < 0.001).
Diagnostic ability of PJC for malignant IPMNs
Table 2 shows the diagnostic ability of PJC for malignant
IPMNs in 90 patients. For all patients, the sensitivity,
specificity and accuracy were 28, 98 and 64%, respect-
ively. Compared to the smear method, the LBC showed
an increased sensitivity and accuracy (sensitivity: 21 to
40%, accuracy: 56 to 76%). Furthermore, the accuracy
with LBC was significantly greater than with the smear
method (P = 0.044). The sensitivity and accuracy of PJC
were increased by a SPACE (sensitivity: 26–50%, accur-
acy: 62–83%), although there were no significant differ-
ences (P = 0.301, P = 0.142).
Evaluating the factors contributing to the accuracy of PJC
for the IPMN diagnosis
Table 3 summarizes the results of the univariate and
multivariate analyses for factors contributing to the ac-
curacy of PJC for the IPMN diagnosis. In the univariate
analysis, LBC (P = 0.044), SPACE (P = 0.142), enhancing
MN > 5mm (P = 0.168), diameter of dilated branch duct
≥ 3 cm (P = 0.043), lymphadenopathy (P = 0.092) and an
increased serum level of CA19–9 (P = 0.002) were sig-
nificant factors (P < 0.2). In the multivariate analysis,
LBC (odds ratio [OR]: 4.25; 95% CI, 1.24–14.54; P =
0.021), enhancing MN > 5mm (OR: 0.23; 95% CI, 0.07–
0.73; P = 0.013), diameter of dilated branch duct ≥ 3 cm
(OR: 4.41; 95% CI, 1.45–13.35; P = 0.009) and increasing
serum level of CA19–9 (OR: 0.24; 95% CI, 0.07–0.79;
P = 0.019) were concluded to be significant factors con-
tributing to the accuracy of PJC for the IPMN diagnosis.
Table 1 Clinicopathologic features of 90 patients with resected IPMNs
All patients (n = 90) Smear method (n = 52) LBC (n = 38) P value
Age (IQR), years 70 (65–74) 69 (64–73) 72 (67–76) 0.084
Sex (male/female) 59/31 37/15 22/16 0.191
Location of main lesion (Ph/Pbt) 50/40 30/22 20/18 0.633
Type of IPMN, n (%) 0.075
BD 33 (37) 21 (40) 12 (32)
Mixed 43 (48) 20 (38) 23 (61)
MD 14 (16) 11 (21) 3 (8)
Pathological diagnosis, n (%) 0.626
L-IGD 47 (52) 24 (46) 23 (61)
HGD 15 (17) 10 (19) 5 (13)
IC 28 (31) 18 (35) 10 (26)
Diameter of dilated branch duct (IQR), mm 27.0 (17.0–40.3) 30.0 (11.0–42.5) 26.0 (19.8–36.8) 0.990
≥ 30 mm, n (%) 41 (46) 27 (52) 14 (37) 0.156
Diameter of MPD (IQR), mm 6.0 (4.0–10.0) 6.0 (4.1–10.0) 6.4 (4.0–10.0) 0.928
5–9 mm, n (%) 35 (39) 20 (38) 15 (39) 0.923
≥ 10 mm, n (%) 23 (26) 14 (27) 9 (24) 0.728
Patients with MN, n (%) 67 (74) 39 (75) 28 (74) 0.888
Height of MN (IQR), mm 7.0 (4.0–15.0) 7.0 (4.0–13.0) 9.5 (4.0–17.5) 0.366
Enhancing MN≥ 5 mm, n (%) 31 (46) 15 (38) 16 (57) 0.130
SPACE, n (%) 12 (13) 1 (2) 11 (29) < .001
IPMN, intraductal papillary mucinous neoplasm; LBC, liquid-based cytology; IQR, interquartile range; Ph, pancreatic head; Pbt, pancreatic body and tail; BD, branch
duct; MD, main duct; L-IGD, low-to intermediate-grade dysplasia; HGD, high-grade dysplasia; IC, invasive cancer; MPD, main pancreatic duct; MN, mural nodule;
SPACE, serial pancreatic juice aspiration cytological examination
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The evaluation for HRS and WF patients
Figure 5 shows the flowchart of HRS and WF patients.
Forty-six patients with HRS were evaluated separately
before and after LBC introduction (smear method: 23,
LBC: 23). Forty-four patients with WF were also evalu-
ated separately (smear method: 29, LBC: 15).
Tables 4 and 5 summarize the clinicopathologic fea-
tures of the 46 patients with HRS and the 44 patients
with WF, respectively. Among the HRS patients, the
median age was 71 years old (IQR: 66–75 years old).
Six (13%) patients had obstructive jaundice. An MPD
diameter ≥ 10 mm was found in 23 (50%) patients.
Enhancing MN > 5mm was found in 31 (72%) pa-
tients. Six (13%) patients underwent SPACE. There
were no patients who underwent a SPACE in the
smear method group, and a SPACE was performed
significantly more frequently in the LBC group than
in the smear method group.
Among the WF patients, the median age was 69 years
old (IQR: 63–74 years old). A dilated branch duct
diameter ≥ 3 cm was found in 20 (45%) patients. Twenty-
four (55%) patients had detectable MN, and the median
height of MN was 3.9 mm (IQR: 3.0–4.8 mm). Six (14%)
patients underwent a SPACE. There were significant dif-
ferences between the two groups in terms of the propor-
tions of patients with a dilated branch duct diameter ≥ 3
cm, the median height of MN, and the proportion
undergoing a SPACE.
Diagnostic ability of PJC for malignant IPMNs in HRS and
WF patients
Table 6 shows the diagnostic ability of PJC. For all pa-
tients, the sensitivity, specificity and accuracy were 33,
94 and 54% in patients with HRS and 15, 100 and 75%
in patients with WF, respectively. In HRS patients, LBC
showed a tendency toward an improvement in accuracy
compared with smear method (smear method: 43% vs.
LBC: 65%; P = 0.139). Furthermore, LBC significantly im-
proved the accuracy compared with smear method in
Table 2 Diagnostic ability of PJC for malignant IPMNs
Sensitivity, (%) Specificity, (%) PPV, (%) NPV, (%) Accuracy, (%)
Smear method (n = 52) 21 (6/28) 96 (23/24) 86 (6/7) 51 (23/45) 56 (29/52)
LBC (n = 38) 40 (6/15) 100 (23/23) 100 (6/6) 72 (23/32) 76 (29/38)
All patients (n = 90) 28 (12/43) 98 (46/47) 92 (12/13) 60 (46/77) 64 (58/90)
PJC pancreatic juice cytology, IPMN intraductal papillary mucinous neoplasm, PPV positive predictive value, NPV negative predictive value; LBC, liquid-based cytology
Table 3 Results of univariate and multivariate analyses for factors contributing to the accuracy of PJC for the IPMN diagnosis (n = 90)
Univariate Multivariate
Factors n Ratio of malignancy,
n (%)
P value Odds ratio 95% CI P value
Age, ≥ 70 years old 48 26 (54) 0.977
Sex, male 59 27 (46) 0.992
Location of main lesion, Ph 50 23 (46) 0.431
MD or mixed-type, yes 57 31 (54) 0.212
LBC, yes 38 15 (39) 0.044 4.25 1.24–14.54 0.021
SPACE, yes 12 4 (33) 0.142 2.04 0.31–13.28 0.455
Obstructive jaundice, yes 6 6 (100) 0.444
Enhancing MN≥ 5 mm, yes 31 19 (61) 0.168 0.23 0.07–0.73 0.013
Diameter of MPD≥ 10 mm, yes 23 14 (61) 0.358
Past history of pancreatitis, yes 10 4 (40) 0.697
Diameter of dilated branch duct ≥3 cm, yes 41 15 (37) 0.043 4.41 1.45–13.35 0.009
Thickness and/or enhancing cyst walls, yes 26 10 (38) 0.276
Abrupt change in caliber of pancreatic duct with distal
pancreatic atrophy, yes
22 16 (73) 0.927
Lymphoadenopathy, yes 4 4 (100) 0.092 0.15 0.01–2.12 0.159
Increasing serum level of CA19–9, yes 22 18 (82) 0.002 0.24 0.07–0.79 0.019
Increasing size of cyst over 5 mm/2 years, yes 15 8 (53) 0.617
IPMN, intraductal papillary mucinous neoplasm; CI, confidence interval; Ph, pancreatic head; MD, main duct; LBC, liquid-based cytology; SPACE, serial pancreatic
juice aspiration cytological examination; MN, mural nodule; MPD, main pancreatic duct; CA19–9, carbohydrate antigen 19–9
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Fig. 5 A flowchart for HRS and WF patients in this study. HRS, high-risk stigmata; WF, worrisome features; LBC, liquid-based cytology
Table 4 Clinicopathologic features of 46 patients with resected IPMNs (HRS patients)
All patients (n = 46) Smear method (n = 23) LBC (n = 23) P value
Age (IQR), years 71 (66–75) 70 (66–73) 71 (66–77) 0.733
Sex (male/female) 27/19 15/8 12/11 0.369
Location of main lesion (Ph/Pbt) 21/25 11/12 10/13 0.767
Type of IPMN, n (%) 0.128
BD 9 (20) 4 (17) 5 (22)
Mixed 25 (54) 10 (43) 15 (65)
MD 12 (26) 9 (39) 3 (13)
Pathological diagnosis, n (%) 0.407
L-IGD 16 (35) 6 (26) 10 (43)
HGD 10 (22) 5 (22) 5 (22)
IC 20 (43) 12 (52) 8 (35)
Obstructive jaundice, n (%) 6 (13) 3 (13) 3 (13) 1.000
Diameter of dilated branch duct (IQR), mm 25.5 (6.0–42.3) 17.0 (0–46.0) 28.0(20.0–42.0) 0.370
≥ 30 mm, n (%) 21 (46) 10 (44) 11 (48) 0.767
Diameter of MPD (IQR), mm 10.0 (5.0–12.0) 10.0 (6.0–13.0) 8.0 (5.0–12.0) 0.205
≥ 10 mm, n (%) 23 (50) 14 (61) 9 (39) 0.140
Patients with MN, n (%) 43 (93) 22 (96) 21 (91) 0.550
Height of MN (IQR), mm 12.0 (7.0–18.0) 11.0 (7.0–17.3) 13.0 (7.5–19.5) 0.626
Enhancing MN≥ 5 mm, n (%) 31 (72) 15 (68) 16 (76) 0.558
SPACE, n (%) 6 (13) 0 (0) 6 (26) 0.009
IPMN, intraductal papillary mucinous neoplasm; HRS, high-risk stigmata; LBC, liquid-based cytology; IQR, interquartile range; Ph, pancreatic head; Pbt, pancreatic
body and tail; BD, branch duct; MD, main duct; L-IGD, low-to intermediate-grade dysplasia; HGD, high-grade dysplasia; IC, invasive cancer; MPD, main pancreatic
duct; MN, mural nodule; SPACE, serial pancreatic juice aspiration cytological examination
Miyamoto et al. BMC Gastroenterology          (2020) 20:319 Page 7 of 11
WF patients (smear method: 66% vs. LBC: 93%; P =
0.043).
Post-ERCP adverse events
Among the 104 patients who underwent ERCP for PJC,
PEP developed in 13 (13%), and pneumonia developed
in 1 (1.0%). The degree of severity of PEP was mild in 7
(6.7%) and moderate in 6 (5.8%); no severe cases of PEP
occurred. All of the patients were treated with conserva-
tional therapy and improved. There were no patients
who needed to cancel or delay their surgery due to the
occurrence of PEP. Among the 104 patients, SPACE was
performed in 14 (13%). Three of the 14 patients
developed PEP (21%). There was no significant differ-
ence between the patients with and without a SPACE in
terms of the frequency of PEP (SPACE: 21% vs. without
SPACE: 11%; P = 0.278).
Discussion
This study is the first to evaluate the efficacy of PJC
using LBC with a large number of surgically resected
IPMN cases. In our study, LBC increased the accuracy of
PJC for a malignant IPMN diagnosis (smear method: 56%
vs. LBC: 76%; P = 0.044) and proved to be a significant fac-
tor influencing an accurate diagnosis of PJC in the multi-
variate analysis (odds ratio [OR]: 3.52; P = 0.021). Second,
Table 5 Clinicopathologic features of 44 patients with resected IPMNs (WF patients)
All patients (n = 44) Smear method (n = 29) LBC (n = 15) P value
Age (IQR), years 69 (63–74) 68 (61–72) 74 (68–76) 0.135
Sex (male/female) 32/12 22/7 10/5 0.516
Location of main lesion (Ph/Pbt) 29/15 19/10 10/5 0.939
Type of IPMN, n (%) 0.341
BD 24 (55) 17 (59) 7 (47)
Mixed 18 (41) 10 (34) 8 (53)
MD 2 (5) 2 (7) 0 (0)
Pathological diagnosis, n (%) 0.105
L-IGD 31 (70) 18 (62) 13 (87)
HGD 5 (11) 5 (17) 0 (0)
IC 8 (18) 6 (21) 2 (13)
Diameter of dilated branch duct (IQR), mm 28.0 (19.3–35.0) 30.0 (19.5–42.0) 23.0 (19.0–29.0) 0.725
≥ 30 mm, n (%) 20 (45) 17 (59) 3 (20) 0.015
Diameter of MPD (IQR), mm 5.0 (4.0–7.0) 5.0 (4.0–7.0) 5.0 (4.0–8.0) 0.542
5–9 mm, n (%) 22 (50) 14 (48) 8 (53) 0.751
Patients with MN, n (%) 24 (55) 17 (59) 7 (47) 0.450
Height of MN (IQR), mm 3.9 (3.0–4.8) 4.0 (3.0–6.0) 3.0 (1.0–4.0) 0.044
SPACE, n (%) 6 (14) 1 (3) 5 (33) 0.006
IPMN, intraductal papillary mucinous neoplasm; WF, worrisome features; LBC, liquid-based cytology; IQR, interquartile range; Ph, pancreatic head; Pbt, pancreatic
body and tail; BD, branch duct; MD, main duct; L-IGD, low-to intermediate-grade dysplasia; HGD, high-grade dysplasia; IC, invasive cancer; MPD, main pancreatic
duct; MN, mural nodule; SPACE, serial pancreatic juice. Aspiration cytological examination
Table 6 Diagnostic ability of PJC for malignant IPMNs (HRS and WF patients)
Sensitivity, (%) Specificity, (%) PPV, (%) NPV, (%) Accuracy, (%)
HRS
Smear method (n = 23) 29 (5/17) 83 (5/6) 83 (5/6) 29 (5/17) 43 (10/23)
LBC (n = 23) 38 (5/13) 100 (10/10) 100 (5/5) 56 (10/18) 65 (15/23)
All patients (n = 46) 33 (10/30) 94 (15/16) 91 (10/11) 43 (15/35) 54 (25/46)
WF
Smear method (n = 29) 9 (1/11) 100 (18/18) 100 (1/1) 64 (18/28) 66 (19/29)
LBC (n = 15) 50 (1/2) 100 (13/13) 100 (1/1) 93 (13/14) 93 (14/15)
All patients (n = 44) 15 (2/13) 100 (31/31) 100 (2/2) 74 (31/42) 75 (33/44)
PJC, pancreatic juice cytology; IPMN, intraductal papillary mucinous neoplasm; HRS, high-risk stigmata; WF, worrisome features; PPV, positive predictive value; NPV,
negative predictive value. LBC, liquid-based cytology
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LBC increased the accuracy of PJC particularly for diag-
nosing malignant IPMN in WF patients (smear method:
66% vs. LBC: 93%; P = 0.043).
The smear method has been used generally due to its
convenience and low cost. However, issues associated
with this method include the fact that the amount of
cells placed on the slide glass varies depending on the
skill of the operator, and dry denaturation causes poor
cell preservation. Previous studies have reported that
these issues accounted for two-thirds of cytological false
negatives [26–28].
With LBC, all collected cells are placed in the fixative,
and the cells required to make a diagnosis are mainly
collected using separation reagents. The cell suspension
is smeared uniformly onto two spots of a glass slide,
with few overlapping cells, so the cell findings at the
margin of the cluster can be analyzed. In addition, the
background of inflammatory cells and mucus is re-
moved, so the tumor cells scattered solitarily can be
evaluated. Furthermore, because the scope of the
speculum is narrowed, the speculum time is reduced.
For these reasons, almost all cells can be efficiently ana-
lyzed. The LBC method is thus superior to the smear
method with regard to assessing both the cellularity and
cytomorphology. For the diagnosis of malignant IPMN,
PJC has low sensitivity due to inadequate cellularity in
most cases [29]. Using LBC, an increased sensitivity (21
to 40%) and negative predictive value (NPV) (51 to 72%)
contributed to the increased accuracy of PJC.
Both the BD SurePath (Nippon Becton Dickinson
Company, Tokyo, Japan) and ThinPrep (Hologic Japan,
Tokyo, Japan) are commonly used LBC technologies in
cervical cytology. These technologies differ by their
methods of producing thin-layer slides. The BD Sure-
Path uses no filters and employs a proprietary cell en-
richment process that separates and reduces mucus,
blood and inflammatory cells. The unnecessary debris is
then trapped in a gradient density material that is re-
moved. In contrast, the ThinPrep uses a membrane that
controls the collection and transfer of diagnostic cells.
Kenyon et al. reported that the addition of mucus did
not reduce the cellularity with the BD SurePath; how-
ever, the cellularity was significantly reduced with Thin-
Prep [30]. They showed that direct obstruction of the
filtration membrane of the ThinPrep due to excess
mucus caused a reduction in the number of diagnostic
cells. We therefore considered that the BD SurePath
might be suitable for the diagnosis of malignant IPMN
with rich mucus.
In patients with HRS, LBC showed a tendency toward
an improved accuracy, although not to a significant de-
gree (smear method: 43% vs. LBC: 65%; P = 0.139). The
median diameter of the MPD was larger in HRS patients
than in WF patients (10.0 mm vs. 5.0 mm; P < 0.001).
Because MPD dilatation without obstruction in IPMN
has been generally considered to be the result of mucus
hypersecretion [31], HRS patients are expected to have
more mucus than WF patients. Even using LBC with the
BD SurePath, the improving effect of LBC was inad-
equate in cases rich in mucus, such as in HRS patients.
However, in the clinical setting, it is important to detect
malignant IPMNs in WF patients.
Enhancing MN > 5mm negatively contributed to the
accuracy of PJC (OR 0.23; P = 0.013). Of the 31 and 59
patients with and without enhancing MN > 5mm, an ac-
curate diagnosis was obtained in 17 (55%) and 41 (69%),
respectively. The pathological diagnoses were as follows:
L-IGD, 12; HGD, 5; and IC, 14 in patients with MN > 5
mm, and L-IGD, 35; HGD, 10; and IC, 14 in patients
without MN > 5mm. The proportion of malignant
IPMN (HGD or IC) was larger in patients with enhan-
cing MN > 5mm than in those without enhancing MN >
5mm (61% vs. 41%; P = 0.063). There was a bias between
populations, and the sensitivity of PJC was low (28%)
while the NPV was relatively high (60%). The accuracy
was thus decreased in the patients with enhancing MN >
5mm. However, enhancing MN > 5mm itself is associ-
ated with malignant IPMN, so surgery should be recom-
mended for patients with HRS, regardless of the results
of PJC.
An elevated serum level of CA19–9 contributed to the
accuracy of PJC (OR 0.24; P = 0.019). Of the 22 patients
with an elevated level of CA19–9, an accurate diagnosis
was obtained in 8 (36%). In contrast, of the 68 patients
with normal levels of CA19–9, an accurate diagnosis
was obtained in 50 (74%). Among the patients with ele-
vated levels of CA19–9, 18 had malignant IPMN (HGD:
3 [14%], IC: 15 [68%]). In contrast, among the patients
with normal levels of CA19–9, 25 had malignant IPMN
(HGD: 12 [18%], IC: 13 [19%]). The proportion of IC
was significantly larger in the patients with elevated
levels of CA19–9 than in those with normal levels of
CA19–9 (P < 0.0001). The sensitivity of PJC was low, but
the NPV was high. Because of the bias between popula-
tions, the accuracy was decreased in the group with ele-
vated levels of CA19–9. However, in the 22 patients
with elevated levels of CA19–9, LBC improved the ac-
curacy, although not to a significant degree (29 to 50%;
P = 0.315). CA19–9 itself was also a useful marker for
detecting IC derived from IPMN.
Yamakawa et al. reported that the sensitivity and ac-
curacy of PJC for a malignant IPMN diagnosis were in-
creased by a SPACE in IPMN patients [15]. Our study
similarly showed that the sensitivity and accuracy of PJC
were increased by a SPACE, although not to a significant
degree (sensitivity: 26 to 50%; P = 0.301, accuracy: 62 to
83%; P = 0.142). Only 12 patients (13%) underwent a
SPACE. Statistically significant differences might have
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been obtained if more patients had undergone a SPACE.
Furthermore, of the 12 patients who underwent a
SPACE, 11 were diagnosed by LBC, so it is necessary to
consider the possibility of confounding by LBC.
Even using LBC methods, the sensitivity of PJC for
malignant IPMN was not sufficient (40%), a PEP oc-
curred in 12.5% of cases. Although the severity of PEP
was only mild or moderate and there were no patients
who needed to cancel or delay their surgery, we should
consider the indication of PJC for surgical candidates. In
this study, among 46 patients with HRS, 30 (65%) had
malignant IPMN. Thus, the findings of HRS are an ad-
equate indication for surgery, and PJC for patient with
HRS may be unnecessary. Among patients with WF, all
of patients with lymphadenopathy and a majority with
increasing serum levels of CA19–9 were malignant
IPMN (100, 82%). In contrast, 37% (15/41) of patients
with a cyst size ≥3 cm had malignant lesions, and the
cyst size was associated with the accuracy of PJC (OR:
4.41, P = 0.009). Given these results, patients with a cyst
size of ≥3 cm without the above 2 WF factors are con-
sidered well-indicated for PJC with LBC.
This study has several limitations. First, this was a
retrospective study. Not all procedures were performed
by the same endoscopists, and not all cytology speci-
mens were evaluated by the same pathologists. Second,
this study had a selection bias, as the indications of PJC
depended in part on the discretion of the attending
physician. Third, the efficacy of SPACE was not evalu-
ated sufficiently because of the lack of patients who
underwent a SPACE. Fourth, there were relatively few
patients with LBC among the WF patients.
Conclusions
In conclusion, LBC improved the accuracy of PJC for
malignant IPMN. Furthermore, in WF patients in par-
ticular, LBC proved useful for the accurate diagnosis.
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